(-0.69%) 5 036.71 points
(-1.08%) 38 045 points
(-0.96%) 15 561 points
(0.10%) $82.89
(-1.63%) $1.626
(0.12%) $2 341.20
(0.05%) $27.36
(0.74%) $922.55
(-0.31%) $0.932
(-0.18%) $10.96
(-0.44%) $0.799
(-0.06%) $92.27
-2.58% KRW 173 700
Live Chart Being Loaded With Signals
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology...
Stats | |
---|---|
Today's Volume | 671 890 |
Average Volume | 1.90M |
Market Cap | 9 204.03B |
EPS | KRW0 ( 2024-03-17 ) |
Next earnings date | ( KRW0 ) 2024-05-12 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW235.18 (0.14%) |
Volume Correlation
ALTEOGEN Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ALTEOGEN Inc. Correlation - Currency/Commodity
ALTEOGEN Inc. Financials
Annual | 2023 |
Revenue: | KRW96.52B |
Gross Profit: | KRW82.23B (85.19 %) |
EPS: | KRW-65.27 |
Q4 | 2023 |
Revenue: | KRW22.35B |
Gross Profit: | KRW1.13B (5.05 %) |
EPS: | KRW-219.99 |
Q3 | 2023 |
Revenue: | KRW21.30B |
Gross Profit: | KRW4.05B (19.01 %) |
EPS: | KRW-147.53 |
Q2 | 2023 |
Revenue: | KRW42.53B |
Gross Profit: | KRW23.71B (55.74 %) |
EPS: | KRW463.58 |
Financial Reports:
No articles found.
ALTEOGEN Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators